Spots Global Cancer Trial Database for malignant melanoma
Every month we try and update this database with for malignant melanoma cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Study of GSK2132231A Antigen-Specific Cancer Immunotherapeutic in Patients With Inoperable Metastatic Cutaneous Melanoma | NCT00896480 | Melanoma | Immunotherapeut... | 18 Years - | GlaxoSmithKline | |
| Fluorescein for Lymphatic Mapping and Sentinel Lymph Node (SLN) Biopsy in Patients With Stage I and II Malignant Melanoma | NCT00847522 | Cancer | Fluorescein | 18 Years - | University of Utah | |
| A Study of Vemurafenib (Zelboraf) in Chinese Participants With BRAF V600 Mutation-Positive Unresectable or Metastatic Melanoma | NCT01910181 | Malignant Melan... | Vemurafenib | 18 Years - | Hoffmann-La Roche | |
| Pre Transplantation Melanoma | NCT04217382 | Malignant Melan... | patient with me... | 18 Years - | Hospices Civils de Lyon | |
| T Cell Receptor Immunotherapy Targeting NY-ESO-1 for Patients With NY-ESO-1 Expressing Melanoma | NCT02062359 | Metastatic Canc... Metastatic Mela... | Anti-NY ESO-1 T... Aldesleukin Cyclophosphamid... Fludarabine | 18 Years - 70 Years | National Institutes of Health Clinical Center (CC) | |
| Efficacy of Chemotherapy Combined With Regional Hypothermia in Advanced Malignant Melanoma Patients With Progressive Soft Tissue Metastases | NCT00264056 | Advanced Metast... Refractory to F... | hyperthermia | 18 Years - 70 Years | Fachklinik Hornheide an der Universität Münster | |
| Study of MDX-010 in Subjects With Unresectable Stage III or Stage IV Malignant Melanoma | NCT00729950 | Malignant Melan... | MDX-010 | 18 Years - | Bristol-Myers Squibb | |
| Study of Heat Shock Protein-Peptide Complex (HSPPC-96) Versus IL-2/DTIC for Stage IV Melanoma | NCT00039000 | Malignant Melan... | HSPPC-96 or Onc... | 18 Years - | Agenus Inc. | |
| Trial of Vaccine Therapy With mRNA- Transfected Dendritic Cells in Patients With Advanced Malignant Melanoma | NCT01278940 | Malignant Melan... | Dendritic Cells... IL-2 | 18 Years - | Oslo University Hospital | |
| Fluorescein for Lymphatic Mapping and Sentinel Lymph Node (SLN) Biopsy in Patients With Stage I and II Malignant Melanoma | NCT00847522 | Cancer | Fluorescein | 18 Years - | University of Utah | |
| A Survey Study to See if Patients Diagnosed With Parkinson's Disease Have Higher Incidence of Melanoma | NCT00203008 | Parkinson's Dis... Malignant Melan... | - | Teva Branded Pharmaceutical Products R&D, Inc. | ||
| Evaluation of a New Vaccine Treatment for Patients With Metastatic Skin Cancer | NCT01149343 | Melanoma | Immunotherapeut... | 18 Years - | GlaxoSmithKline | |
| Phase 1b/2 Study of the Combination of IMCgp100 With Durvalumab and/or Tremelimumab in Advanced Cutaneous Melanoma | NCT02535078 | Malignant Melan... | Tebentafusp (IM... durvalumab tremelimumab | 18 Years - | Immunocore Ltd | |
| Phase Ib of L-NMMA and Pembrolizumab | NCT03236935 | Non-Small Cell ... Malignant Melan... Head and Neck S... Classical Hodgk... Urothelial Carc... DNA Repair-Defi... | L-NMMA Pembrolizumab | 18 Years - | The Methodist Hospital Research Institute | |
| ImmuniCell® in Patients With Advanced Cancers | NCT02459067 | Malignant Melan... Non-small Cell ... Renal Cell Canc... | ImmuniCell® | 18 Years - | TC Biopharm | |
| Co-stimulatory Markers and Vitamin D Status in Anti-PD1 Treated Melanoma Patients | NCT03197636 | Malignant Melan... | Pembrolizumab | 18 Years - 90 Years | Aarhus University Hospital | |
| Sample Collection From Melanoma Patients | NCT00507325 | Melanoma | Blood Sample Tumor Sample | - | M.D. Anderson Cancer Center | |
| Early Diagnosis of Malignant Transformation of Pigmentary Skin Lesions | NCT01167998 | Malignant Melan... Pigmented Nevi Skin Neoplasm | 18 Years - | Hadassah Medical Organization | ||
| Vemurafenib and Cobimetinib Combination in BRAF Mutated Melanoma With Brain Metastasis | NCT02537600 | Malignant Melan... | Cobimetinib + V... | 18 Years - | Center Eugene Marquis | |
| Chemotherapy Followed by gp100 Lymphocytes and Aldesleukin to Treat Melanoma | NCT00665470 | Skin Cancer Metastatic Mela... | Aldesleukin | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| A Study of the Effect of Food on the Pharmacokinetics of Single Dose RO5185426 And the Safety And Efficacy of Continuous Administration in Patients With BRAF V600E Mutation-Positive Metastatic Melanoma | NCT01264380 | Malignant Melan... | RO5185426 RO5185426 RO5185426 | 18 Years - | Hoffmann-La Roche | |
| SU011248 in Patients With Metastatic Mucosal or Acral/Lentiginous Melanoma | NCT00577382 | Mucosal Lentigi... Acral Lentigino... | Sunitinib | 18 Years - | Dana-Farber Cancer Institute | |
| Ipilimumab and All-Trans Retinoic Acid Combination Treatment of Advanced Melanoma | NCT02403778 | Melanoma | VESANOID Ipilimumab | 18 Years - 89 Years | University of Colorado, Denver | |
| Pilot Study to Evaluate the Effects of a Vaccine (HSPPC-96) Combined With Ipilimumab in Patients With Advanced Melanoma | NCT02452281 | Melanoma | ipilimumab HSPPC-96 | 18 Years - | The University of Texas Health Science Center, Houston | |
| Neoadjuvant Vemurafenib + Cobimetinib + Atezolizumab in Melanoma: NEO-VC | NCT02303951 | Malignant Melan... | Vemurafenib Cobimetinib Atezolizumab | 18 Years - | University Hospital Tuebingen | |
| Encorafenib + Binimetinib + Pembrolizumab in Patients With Unresectable or Metastatic BRAF V600 Mutant Melanoma | NCT02902042 | Malignant Melan... | Encorafenib Binimetinib Pembrolizumab Pembrolizumab a... | 18 Years - | University Hospital, Essen | |
| International Melanoma Algorithm Training Study - IMATS | NCT00966173 | Malignant Melan... | SciBase III Ele... | 18 Years - | SciBase AB | |
| A Survey Study to See if Patients Diagnosed With Parkinson's Disease Have Higher Incidence of Melanoma | NCT00203008 | Parkinson's Dis... Malignant Melan... | - | Teva Branded Pharmaceutical Products R&D, Inc. | ||
| Phase II Trial of Ontak With Metastatic Melanoma | NCT00299689 | Malignant Melan... | Denileukin dift... | 18 Years - | James Graham Brown Cancer Center | |
| Encorafenib + Binimetinib + Pembrolizumab in Patients With Unresectable or Metastatic BRAF V600 Mutant Melanoma | NCT02902042 | Malignant Melan... | Encorafenib Binimetinib Pembrolizumab Pembrolizumab a... | 18 Years - | University Hospital, Essen | |
| Sample Collection From Melanoma Patients | NCT00507325 | Melanoma | Blood Sample Tumor Sample | - | M.D. Anderson Cancer Center | |
| A FIH Study of PF-07284890 in Participants With BRAF V600 Mutant Solid Tumors With and Without Brain Involvement | NCT04543188 | Malignant Melan... Carcinoma, Non-... Brain Neoplasms... Brain Neoplasms Malignant Neopl... | PF-07284890 Binimetinib Midazolam | 16 Years - | Pfizer | |
| BRIM-P: A Study of Vemurafenib in Pediatric Patients With Stage IIIC or Stage IV Melanoma Harboring BRAFV600 Mutations | NCT01519323 | Malignant Melan... | vemurafenib | 12 Years - 17 Years | Hoffmann-La Roche | |
| Study of CP-675,206 in Refractory Melanoma | NCT00254579 | Refractory Mela... | CP-675,206 | 18 Years - | AstraZeneca | |
| A Study to Investigate the Efficacy and Safety of an Infusion of IOV-4001 in Adult Participants With Unresectable or Metastatic Melanoma or Stage III or IV Non-small-cell Lung Cancer | NCT05361174 | Unresectable Me... Metastatic Mela... Stage III Non-s... Stage IV Non-sm... | IOV-4001 | 18 Years - | Iovance Biotherapeutics, Inc. | |
| Study to Assess the Tolerability of a Bispecific Targeted Biologic IMCgp100 in Malignant Melanoma | NCT01211262 | Malignant Melan... | IMCgp100 | 18 Years - | Immunocore Ltd | |
| Dabrafenib and Trametinib for BRAF-inhibitor Pretreated Patients | NCT02296996 | Malignant Melan... | Dabrafenib + Tr... | 18 Years - | Universitair Ziekenhuis Brussel | |
| Expanded Access Program With Nivolumab in Combination With Ipilimumab in Patients With Tumors Unable to be Removed by Surgery or Metastatic Melanoma | NCT02186249 | Malignant Melan... | Nivolumab Ipilimumab | 18 Years - | Bristol-Myers Squibb | |
| A Randomized Controlled Phase II Trial With Intradermal IMO-2125 in Pathological Tumor Stage (p) T3-4 cN0M0 Melanoma | NCT04126876 | Malignant Melan... | Tilsotolimod Saline (0.9% so... | 18 Years - | Amsterdam UMC, location VUmc | |
| Melanoma Metastasized to the Brain and Steroids | NCT03563729 | Malignant Melan... | Pembrolizumab I... Ipilimumab Inje... Nivolumab Injec... Encorafenib Binimetinib Dabrafenib Trametinib | 18 Years - | Herlev Hospital | |
| Multicentre, Dose Finding, Ph II,CP-4055 in Comb. With Sorafenib - Patients With Metastatic Malignant Melanoma | NCT00498836 | Malignant Melan... | CP-4055 Sorafenib (Nexa... | 18 Years - | Clavis Pharma | |
| Pegylated Interferon-alpha-2a in Patients With Malignant Melanoma Stage IIA-IIIB | NCT00204529 | Melanoma | pegylated inter... interferon-alph... | 18 Years - 75 Years | University Hospital Tuebingen | |
| RAPA-201 Therapy of Solid Tumors | NCT05144698 | Solid Tumor Breast Cancer Small Cell and ... Triple Negative... Gastric Cancer Esophageal Aden... Gastric Junctio... Esophageal Squa... Head and Neck C... Squamous Cell C... Squamous Cell C... Squamous Cell C... Squamous Cell C... Carcinoma of Un... Bladder Cancer Malignant Melan... | RAPA-201 Rapamy... Chemotherapy Pr... | 18 Years - | Rapa Therapeutics LLC | |
| Standard Palliative Care Versus Standard Palliative Care Plus Polychemotherapy in Metastasized Malignant Melanoma | NCT00226473 | Metastatic Mela... | Cisplatin, Vind... | 18 Years - 75 Years | Dermatologic Cooperative Oncology Group | |
| E6201 Plus Dabrafenib for the Treatment of Metastatic Melanoma Central Nervous System Metastases (CNS) | NCT03332589 | Malignant Melan... Brain Metastase... | E6201 E6201 plus dabr... | 18 Years - | Spirita Oncology, LLC | |
| GM103 Intratumoral Injection in Patients With Locally Advanced, Unresectable, Refractory and/or Metastatic Solid Tumors | NCT06265025 | Head and Neck C... Malignant Melan... Colorectal Canc... Renal Cell Carc... Cervical Cancer Breast Cancer | GM103 (Part A) GM103 (Part B) GM103 and Pembr... | 18 Years - | GeneMedicine Co., Ltd. | |
| Study of the Effects of Pembrolizumab in Patients With Advanced Solid Tumors | NCT02644369 | Squamous Cell C... Triple Negative... Epithelial Ovar... Malignant Melan... Advanced Solid ... | Pembrolizumab | 18 Years - | University Health Network, Toronto | |
| A Study of Avastin (Bevacizumab) in Combination With Fotemustine in Patients With Metastatic Melanoma | NCT01069627 | Malignant Melan... | bevacizumab [Av... fotemustine | 18 Years - | Hoffmann-La Roche | |
| SCIB1 in Melanoma Patients Receiving Either Nivolumab With Ipilimumab or Pembrolizumab (The SCOPE Study) | NCT04079166 | Malignant Melan... Melanoma (Skin) Melanoma Stage ... Melanoma Stage ... | SCIB1 DNA vacci... | 18 Years - | Scancell Ltd | |
| Evaluation of Interferon-Lovastatin Therapy for Malignant Melanoma | NCT00963664 | Melanoma Malignant Melan... | lovastatin interferon alfa... | 18 Years - | NeoPlas Innovation | |
| A Personal Cancer Vaccine (NEO-PV-01) w/ Nivolumab for Patients With Melanoma, Lung Cancer or Bladder Cancer | NCT02897765 | Urinary Bladder... Bladder Tumors Transitional Ce... Malignant Melan... Melanoma Skin Cancer Carcinoma, Non-... Lung Cancer | NEO-PV-01 Nivolumab Adjuvant | 18 Years - | BioNTech SE | |
| Chemotherapy Followed by Infusion of DMF5 Cells to Treat Metastatic Melanoma | NCT00924001 | Melanoma Malignant Melan... Melanoma, Exper... | DMF5 Melanoma R... Cyclophosphamid... Fludarabine Aldesleukin | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| A Study of Vemurafenib (RO5185426) in Comparison With Dacarbazine in Previously Untreated Patients With Metastatic Melanoma (BRIM 3) | NCT01006980 | Malignant Melan... | Vemurafenib Dacarbazine | 18 Years - | Hoffmann-La Roche | |
| Immunostimulating Interstitial Laser Thermotherapy in Malignant Melanoma | NCT02650492 | Melanoma Malignant Melan... | Immunostimulati... | 18 Years - | Clinical Laserthermia Systems AB | |
| Safety and Immunogenicity of CYT004-MelQbG10 Vaccine With and Without Adjuvant in Advanced Stage Melanoma Patients | NCT00651703 | Malignant Melan... | CYT004-MelQbG10... CYT004-MelQbG10... CYT004-MelQbG10... CYT004-MelQbG10... | 18 Years - | Cytos Biotechnology AG | |
| Fluorescence Imaging in Sentinel Lymph Node Biopsy for Breast Cancer and Melanoma | NCT02316795 | Breast Cancer Cancer of Breas... Cancer of the B... Melanoma Malignant Melan... | Sentinel lymph ... Goggle-based de... Indocynanine Gr... | 18 Years - | Washington University School of Medicine | |
| Efficacy Study of IL-21 to Treat Metastatic Melanoma | NCT00336986 | Cancer Malignant Melan... | recombinant int... | 18 Years - | Novo Nordisk A/S | |
| GM-CSF as Adjuvant Therapy of Melanoma | NCT00350597 | Malignant Melan... | Granulocyte-Mac... | 14 Years - | Northern California Melanoma Center | |
| CP-675,206 In Patients With Advanced Melanoma | NCT00086489 | Malignant Melan... | CP-675,206 CP-675,206 | 18 Years - | AstraZeneca | |
| Phase 1B Study Evaluating Alternative Routes of Administration of CMP-001 in Combination With Pembrolizumab in Participants With Advanced Melanoma | NCT03084640 | Malignant Melan... | CMP-001 Pembrolizumab CMP-001 | 18 Years - | Regeneron Pharmaceuticals | |
| Effect of rIL-21 on Metastases in Lymph Nodes in Melanoma Skin Cancer | NCT00601861 | Cancer Malignant Melan... | recombinant int... | 18 Years - | Novo Nordisk A/S | |
| Transfected Dendritic Cell Based Therapy for Patients With Breast Cancer or Malignant Melanoma | NCT00978913 | Breast Cancer Malignant Melan... | DC vaccine | 18 Years - | Herlev Hospital | |
| Vaccination With Tumor mRNA in Metastatic Melanoma - Fixed Combination Versus Individual Selection of Targeted Antigens | NCT00204516 | Malignant Melan... | mRNA coding for... GM-CSF | 18 Years - 80 Years | University Hospital Tuebingen | |
| Phase I/II Trial of Valproic Acid and Karenitecin for Melanoma | NCT00358319 | Malignant Melan... | Karenitecin Valproic Acid | 18 Years - | H. Lee Moffitt Cancer Center and Research Institute | |
| Rovalpituzumab Tesirine in Delta-Like Protein 3-Expressing Advanced Solid Tumors | NCT02709889 | Malignant Melan... Medullary Thyro... Glioblastoma Large-Cell Neur... Neuroendocrine ... High Grade Gast... Other Neuroendo... Other Solid Tum... | Rovalpituzumab ... Dexamethasone | 18 Years - 99 Years | AbbVie | |
| A Trial of ABI-007 Versus Dacarbazine in Previously Untreated Patients With Metastatic Malignant Melanoma | NCT00864253 | Malignant Melan... | ABI-007 Dacarbazine | 18 Years - | Celgene | |
| PLX3397 KIT in Acral aNd mucOsal Melanoma | NCT02071940 | Malignant Melan... | PLX3397 | 18 Years - | The Christie NHS Foundation Trust | |
| Vaccination With Tumor mRNA in Metastatic Melanoma - Fixed Combination Versus Individual Selection of Targeted Antigens | NCT00204516 | Malignant Melan... | mRNA coding for... GM-CSF | 18 Years - 80 Years | University Hospital Tuebingen | |
| IL-2 "SELECT" Tissue Collection Protocol in Patients With Advanced Melanoma | NCT01288963 | Malignant Melan... | IL-2 | 18 Years - | Beth Israel Deaconess Medical Center | |
| A Study of DEDN6526A in Patients With Metastatic or Unresectable Melanoma | NCT01522664 | Malignant Melan... | DEDN6526A | 18 Years - | Genentech, Inc. | |
| Clinical Study of CMP-001 in Combination With Pembrolizumab or as a Monotherapy | NCT02680184 | Melanoma | CMP-001 Pembrolizumab | 18 Years - | Regeneron Pharmaceuticals | |
| Tinostamustine and Nivolumab in Advanced Melanoma | NCT03903458 | Malignant Melan... | Tinostamustine | 18 Years - | Cantonal Hospital of St. Gallen | |
| A Study for the Treatment of Unresectable Stage III or Metastatic Stage IV Melanoma | NCT00281541 | Melanoma | YM155 | 18 Years - | Astellas Pharma Inc | |
| Evaluating the Efficacy and Safety of a Sequencing Schedule of Cobimetinib Plus Vemurafenib Followed by Immunotherapy With an Anti- PD-L1 Antibody in Patients With Unresectable or Metastatic BRAF V600 Mutant Melanoma | NCT02902029 | Malignant Melan... | Vemurafenib Cobimetinib Atezolizumab | 18 Years - | University Hospital, Essen | |
| Expanded Access Program With Nivolumab in Combination With Ipilimumab in Patients With Tumors Unable to be Removed by Surgery or Metastatic Melanoma | NCT02186249 | Malignant Melan... | Nivolumab Ipilimumab | 18 Years - | Bristol-Myers Squibb | |
| Pilot Study to Evaluate the Effects of a Vaccine (HSPPC-96) Combined With Ipilimumab in Patients With Advanced Melanoma | NCT02452281 | Melanoma | ipilimumab HSPPC-96 | 18 Years - | The University of Texas Health Science Center, Houston | |
| Study of Dabrafenib+Trametinib in the Adjuvant Treatment of Stage III BRAF V600+ Melanoma After Complete Resection to Evaluate the Impact on Pyrexia Related Outcomes | NCT03551626 | Malignant Melan... | Dabrafenib Trametinib | 18 Years - | Novartis | |
| Recombinant Human Adenovirus Type 5 Injection Combined With PD-1 Monoclonal Antibody and Nab-paclitaxel in the Treatment of Patients With Liver Metastases From Malignant Melanoma | NCT05664139 | Malignant Melan... Liver Metastase... | Recombinant Hum... | 18 Years - 75 Years | Fujian Cancer Hospital | |
| Overcoming Primary Resistance to Immunotherapy in Metastatic Melanoma | NCT05304546 | Malignant Melan... Metastatic Mela... Immunotherapy BRAF V600E Malignant Melan... | Pembrolizumab Encorafenib Binimetinib | 18 Years - | Sheba Medical Center | |
| Carbon Ion Radiation Therapy in the Treatment of Mucous Melanomas of the Female Lower Genital Tract | NCT05478876 | Malignant Melan... Gynecologic Can... | carbon ion radi... | 20 Years - 80 Years | CNAO National Center of Oncological Hadrontherapy |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
